CA2708679C - Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer - Google Patents

Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer Download PDF

Info

Publication number
CA2708679C
CA2708679C CA2708679A CA2708679A CA2708679C CA 2708679 C CA2708679 C CA 2708679C CA 2708679 A CA2708679 A CA 2708679A CA 2708679 A CA2708679 A CA 2708679A CA 2708679 C CA2708679 C CA 2708679C
Authority
CA
Canada
Prior art keywords
gemcitabine
treatment
formula
pancreatic cancer
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2708679A
Other languages
English (en)
French (fr)
Other versions
CA2708679A1 (en
Inventor
Lyne Gagnon
Lilianne Geerts
Christopher Penney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CA2708679A1 publication Critical patent/CA2708679A1/en
Application granted granted Critical
Publication of CA2708679C publication Critical patent/CA2708679C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2708679A 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer Active CA2708679C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
CA2708679A1 CA2708679A1 (en) 2009-06-25
CA2708679C true CA2708679C (en) 2016-11-15

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708679A Active CA2708679C (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Country Status (15)

Country Link
US (1) US8946190B2 (cg-RX-API-DMAC7.html)
EP (1) EP2231166B1 (cg-RX-API-DMAC7.html)
JP (1) JP5473937B2 (cg-RX-API-DMAC7.html)
KR (1) KR101603351B1 (cg-RX-API-DMAC7.html)
CN (1) CN101903028B (cg-RX-API-DMAC7.html)
AU (1) AU2008338204B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0821395A2 (cg-RX-API-DMAC7.html)
CA (1) CA2708679C (cg-RX-API-DMAC7.html)
DK (1) DK2231166T3 (cg-RX-API-DMAC7.html)
ES (1) ES2414617T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010006867A (cg-RX-API-DMAC7.html)
NZ (1) NZ586249A (cg-RX-API-DMAC7.html)
PT (1) PT2231166E (cg-RX-API-DMAC7.html)
TW (1) TWI448290B (cg-RX-API-DMAC7.html)
WO (1) WO2009076761A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029126T2 (en) 2009-05-04 2017-02-28 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical uses
EP2632452B1 (en) 2010-10-27 2018-09-26 Prometic Pharma Smt Limited Compounds and compositions for the treatment of cancer
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
ES2748562T3 (es) * 2013-02-28 2020-03-17 Basf As Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462964B1 (en) * 1989-03-13 1998-07-22 Cellegy Pharmaceuticals, Inc. Topical compositions containing aliphatic amines for the treatment of skin diseases
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
HUP0303817A3 (en) * 2001-04-18 2009-10-28 Prometic Biosciences Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
WO2003020210A2 (en) * 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
DE602004018902D1 (de) 2003-02-07 2009-02-26 Prometic Biosciences Inc Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
MX2010006867A (es) 2010-08-31
CN101903028A (zh) 2010-12-01
PT2231166E (pt) 2013-06-17
US20100273731A1 (en) 2010-10-28
KR101603351B1 (ko) 2016-03-14
HK1151244A1 (en) 2012-01-27
TW200934494A (en) 2009-08-16
TWI448290B (zh) 2014-08-11
KR20100101134A (ko) 2010-09-16
JP5473937B2 (ja) 2014-04-16
US8946190B2 (en) 2015-02-03
NZ586249A (en) 2012-05-25
CA2708679A1 (en) 2009-06-25
EP2231166A1 (en) 2010-09-29
JP2011506492A (ja) 2011-03-03
BRPI0821395A2 (pt) 2015-06-16
ES2414617T3 (es) 2013-07-22
DK2231166T3 (da) 2013-06-24
CN101903028B (zh) 2013-06-05
EP2231166B1 (en) 2013-03-20
AU2008338204A1 (en) 2009-06-25
EP2231166A4 (en) 2012-02-22
AU2008338204B2 (en) 2015-03-05
WO2009076761A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
CA2708679C (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
US20010018445A1 (en) Pharmaceutical composition for the treatment of hepatocellular carcinoma
CN115414351B (zh) pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用
WO2012075754A1 (zh) 一种治疗急性淋巴白血病的复方药物组合物
CN111514140B (zh) 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
CN116115623B (zh) 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用
CN115135326B (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
HK1151244B (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
WO2022225045A1 (ja) グレリン抵抗性を伴う悪液質の治療剤又は予防剤
HU225988B1 (en) Use of cytidine-phosphocholine for producing pharmaceutical compositions for diabetic neuropathy
CA2191230C (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
JP4091639B2 (ja) チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤
CN111558045A (zh) 一种治疗肺癌的药物组合物
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
CN113440534A (zh) 一种毛蕊花糖苷在制备药物中的应用
CN110227083A (zh) 一种含氯化钆和双胍类降糖药的药物组合物及其用途
ES2357245T3 (es) Inhibidor de los pólipos intestinales.
CN113244242A (zh) 甘草次酸、甘草酸在预防或治疗肺炎/肺纤维化中的应用
JP2024506336A (ja) 膠芽腫の治療方法
CN119015282A (zh) 一种甲基喹啉脲类化合物防治恶性肿瘤恶病质的用途
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
CN110876803A (zh) 一种包含乳蛋白和油酸的药物组合物
Yamagiwa et al. Hepatic arterial chemoembolization as an initial treatment for hepatoblastoma
CN107281462A (zh) 沙奎拉韦减轻伊立替康毒性的医药新用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131216